The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population

Bibliography

• Roger VL, Go AS, Lloyd-Jones DM, Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012;125(1):e2-e220
   PubMed Web of Science ®Google Scholar
• Dell'Italia LJ. Translational success stories: angiotensin receptor 1 antagonists in heart failure. Circ Res 2011;109(4):437-52
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD, 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57(19):1920-59
   PubMedGoogle Scholar
• Lindenfeld J, Albert NM, Boehmer JP, HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16(6):e1-194
   PubMed Web of Science ®Google Scholar
• McMurray J, Ostergren J, Pfeffer M, Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003;5(3):261-70
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-75
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906
   PubMed Web of Science ®Google Scholar
• Novartis. Valsartan - United States Package Insert. 2012
   Google Scholar
• European Medicines Agency. List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diovan_30/WC500007493.pdf 2009
   Google Scholar
• Criscione L, Bradley WA, Bühlmayer P, Valsartan: preclinical and Clinical Profile of an Antihypertensive Angiotensin-II Antagonist. Cardiovasc Drug Rev 1995;13(3):230-50
   Google Scholar
• Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011;12(1):1-7
   PubMed Web of Science ®Google Scholar
• Croom KF, Keating GM. Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction. Am J Cardiovasc Drugs 2004;4(6):395-404
   PubMedGoogle Scholar
• Zairis MN, Tsiaousis GZ, Georgilas AT, Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol 2010;141(3):284-90
   PubMed Web of Science ®Google Scholar
• Dandona P, Kumar V, Aljada A, Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88(9):4496-501
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48(1):73-9
   PubMed Web of Science ®Google Scholar
• Shishido T, Konta T, Nishiyama S, Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets). Clin Exp Hypertens 2011;33(2):117-23
   PubMed Web of Science ®Google Scholar
• Anand IS, Kuskowski MA, Rector TS, Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005;112(8):1121-7
   PubMed Web of Science ®Google Scholar
• Deswal A, Petersen NJ, Feldman AM, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103(16):2055-9
   PubMed Web of Science ®Google Scholar
• Manabe S, Okura T, Watanabe S, Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46(6):735-9
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Malacco E, Khder Y, Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27(5):578-87
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circu Physiol 2011;301(6):H2181-90
   PubMed Web of Science ®Google Scholar
• Yang J, Jiang H, Ding JW, Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 2009;330(1-2):39-46
   PubMed Web of Science ®Google Scholar
• Jug B, Vene N, Salobir BG, Prognostic impact of haemostatic derangements in chronic heart failure. Thromb Haemost 2009;102(2):314-20
   PubMed Web of Science ®Google Scholar
• Weir MR, Hollenberg NK, Zappe DH, Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J Hypertens 2010;28(1):186-93
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Zannad F, Radauceanu A, Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007;100(2):222-6
   PubMed Web of Science ®Google Scholar
• Deppe S, Boger RH, Weiss J, Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 2010;6(7):863-71
   PubMed Web of Science ®Google Scholar
• Erbe DV, Gartrell K, Zhang YL, Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006;45(3):154-62
   PubMed Web of Science ®Google Scholar
• Kajiya T, Ho C, Wang J, Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011;29(12):2476-83
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, Chiang YT, Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999;13(4):275-81
   PubMed Web of Science ®Google Scholar
• Oparil S, Dyke S, Harris F, The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18(5):797-810
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, Weinberger M, Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29(1):61-73
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363(9426):2049-51
   PubMed Web of Science ®Google Scholar
• Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997;52(2):115-20
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Flesch G, Muller P, Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27(1):59-71
   PubMed Web of Science ®Google Scholar
• Sunkara G, Yeh C, Ligueros-Saylan M, Assessment of Ethnic Differences in the Pharmacokinetics and Pharmacodynamics of Valsartan. J Bioequivalence Bioavailability 2010;2(6):120-4
   Google Scholar
• Muller P, Flesch G, de Gasparo M, Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997;52(6):441-9
   PubMed Web of Science ®Google Scholar
• Prasad PP, Yeh CM, Gurrieri P, Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol 2002;40(5):801-7
   PubMed Web of Science ®Google Scholar
• Zeneca A. Candesartan - United States Package Insert. 2012
   Google Scholar
• Takeda. Azilsartan - United States Package Insert. 2012
   Google Scholar
• Merck. Losartan - United States Package Insert. 2012
   Google Scholar
• Ingelheim B. Telmisartan - United States Package Insert. 2012
   Google Scholar
• Forest. Olmesartan - United States Package Insert. 2012
   Google Scholar
• Aventis B-MSS. Irbesartan - United States Package Insert. 2012
   Google Scholar
• Abbott. Eprosartan - United States Package Insert. 2012
   Google Scholar
• Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44(8):797-814
   PubMed Web of Science ®Google Scholar
• Croom KF, Plosker GL. Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs 2008;68(11):1543-69
   PubMed Web of Science ®Google Scholar
• Fenton C, Scott LJ. Candesartan cilexetil: a review of its use in the management of chronic heart failure. Drugs 2005;65(4):537-58
   PubMed Web of Science ®Google Scholar
• Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66(1):51-83
   PubMed Web of Science ®Google Scholar
• Plosker GL. Eprosartan: a review of its use in hypertension. Drugs 2009;69(17):2477-99
   PubMed Web of Science ®Google Scholar
• Weber M. Clinical efficacy of eprosartan. Pharmacotherapy 1999;19(4 Pt 2):95S-101S
   Google Scholar
• Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 2011;45(12):1506-15
   PubMed Web of Science ®Google Scholar
• Sioufi A, Marfil F, Jaouen A, The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19(4):237-44
   PubMed Web of Science ®Google Scholar
• Colussi DM, Parisot C, Rossolino ML, Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 1997;37(3):214-21
   PubMedGoogle Scholar
• Brookman LJ, Rolan PE, Benjamin IS, Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62(3):272-8
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006;79(5):427-39
   PubMed Web of Science ®Google Scholar
• Maillard MP, Wurzner G, Nussberger J, Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002;71(1):68-76
   PubMedGoogle Scholar
• Zannad F, Alla F, Dousset B, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102(22):2700-6
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374(9704):1840-8
   PubMed Web of Science ®Google Scholar
• Svanstrom H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 2012;307(14):1506-12
   PubMedGoogle Scholar
• Cho YR, Kim YD, Park TH, The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial. Trials 2011;12:247; PMCID: 3247852
   PubMedGoogle Scholar
• Solomon SD, Zelenkofske S, McMurray JJ, Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352(25):2581-8
   PubMed Web of Science ®Google Scholar
• Baruch L, Anand I, Cohen IS, Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99(20):2658-64
   PubMedGoogle Scholar
• Cohn JN, Tognoni G, Glazer R, Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail 2000;2(4):439-46
   PubMedGoogle Scholar
• Maggioni AP, Anand I, Gottlieb SO, Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40(8):1414-21
   PubMed Web of Science ®Google Scholar
• Krum H, Carson P, Farsang C, Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6(7):937-45
   PubMedGoogle Scholar
• Reed SD, Friedman JY, Velazquez EJ, Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004;148(1):122-8
   PubMedGoogle Scholar
• Velazquez EJ, Pfeffer MA, McMurray JV, VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003;5(4):537-44
   PubMed Web of Science ®Google Scholar
• Reed SD, Radeva JI, Weinfurt KP, Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). Am Heart J 2005;150(2):323-9
   PubMedGoogle Scholar
• Kostis JB, Kim HJ, Rusnak J, Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005;165(14):1637-42
   PubMedGoogle Scholar
• Haymore BR, Yoon J, Mikita CP, Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008;101(5):495-9
   PubMed Web of Science ®Google Scholar
• Bangalore S, Messerli FH. Valsartan inefficacy or ill-effects of concomitant medications!. Am J Cardiol 2010;106(4):602-3
   PubMedGoogle Scholar
• Morimoto T, Gandhi TK, Fiskio JM, Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med 2004;19(6):684-91; PMCID: 1492376
   PubMedGoogle Scholar
• Sica DA, Hess M. Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. Congest Heart Fail 2004;10(5):259-64
   PubMedGoogle Scholar
• Granger CB, McMurray JJ, Yusuf S, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-6
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372(9644):1174-83
   PubMed Web of Science ®Google Scholar
• Phillips CO, Kashani A, Ko DK, Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007;167(18):1930-6
   PubMedGoogle Scholar
• Pitt B, Bakris G, Ruilope LM, Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118(16):1643-50
   PubMedGoogle Scholar
• Pfeffer MA, Swedberg K, Granger CB, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-66
   PubMed Web of Science ®Google Scholar
• Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004;21(2):76-86
   PubMed Web of Science ®Google Scholar
• Hedner T, Oparil S, Rasmussen K, A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12(4 Pt 1):414-17
   PubMed Web of Science ®Google Scholar